Project Grant R01HL173838
Award Date 8/5/25
Completion Date 7/31/30
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to evaluate the implementation of a heart failure polypill strategy in India. The award, valued at $498,129.23 and starting on December 9, 2024, supports a multi-center randomized clinical trial to assess whether a polypill containing guideline-directed medications can reduce cardiovascular mortality and heart failure hospitalizations compared to usual care in adults...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- The University of Texas Southwestern Medical Center received a $685,724 project grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct a multi-center observational study on the association between ventilation and cardiac arrest outcomes. The study will leverage data from a large clinical trial database to analyze ventilation metrics using a machine learning algorithm developed to measure ventilation during continuous chest...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $670,890 to The University of Texas Southwestern Medical Center to investigate the effects of chronic lower leg heating on vascular and neural mechanisms in pregnant women with obesity. The goal is to determine if this intervention can improve vascular endothelial function and attenuate sympathetic vasoconstriction, potentially reducing the risk of hypertensive...
- The federal Cooperative Agreement award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, with a total funding amount of $952,993.00 and a performance period from July 30, 2025 to June 30, 2032, will support a clinical study entitled "PREEMPT: Prospective Randomized Evaluation and Management of Premature Atherosclerosis." The study aims to develop optimal strategies for screening,...
- This federal Project Grant award of $1,356,922.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of novel hydrogel-coated electrospun (HES) biomaterials for replacement heart valves. The key objectives are to: Identify optimal biomaterial and leaflet geometry characteristics to develop replacement heart valves with greater durability, resistance to thrombosis, and improved hemodynamics. This will leverage the...
- This federal Project Grant award of $362,250 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to evaluate the impact of treating elevated blood pressure in the inpatient setting on patient outcomes. The project, titled "Evaluating Whether Treating Elevated Blood Pressure in the Inpatient Setting Impacts Patient Outcomes: The ACT-BP Pilot," aims to obtain key knowledge needed to conduct a larger randomized clinical trial by...
- This Project Grant award, totaling $499,585.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Health Science Center at Tyler. The project aims to develop a novel therapeutic strategy called "Two-Target Fibrinolytic Therapy" (T2FT) to increase the efficacy of empyema treatment. The research involves preclinical testing and optimization of a combination therapy using alteplase (ALT), a docking site...
- This $734,722 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized controlled clinical trial to assess the impact of disclosing systolic blood pressure polygenic risk scores on blood pressure control, healthy lifestyle adherence, and cardiometabolic health among 300 hypertensive adults aged 18-55 in the United States. The study aims to evaluate whether providing individuals with information about their...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $538,998 Project Grant to Texas A&M AgriLife Research under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The 4-year "Deep in the Heart" project aims to develop and evaluate a community-engaged intervention to prevent obesity and cardiovascular disease risk factors in rural South Texas women. The project will involve formative research, a multilevel intervention including group classes, a...